Table 2.
Results of our experience of PRRT retreatment
| Evaluation criteria | 90Y-PRRT treatment | 177Lu-PRRT retreatment | P-value |
|---|---|---|---|
| Number of patients | 26 | 26 | |
| Median activity (range) | 10.8 GBq (5–14.9) | 16.5 GBq (5.5–22.2) | |
| Median number of cycles | 5 (2–7) | 5 (2–5) | |
| CR | 1 | 1 | |
| PR | 3 | 1 | |
| SD | 22 | 20 | |
| PD | NA | 4 | |
| Median PFS, months (95% CI) | 28 (20–36) | 22 (16–nr) | 0.529 |
| Median OS, months (95% CI) | 36 (4–70) |
Note: © Springer-Verlag Berlin Heidelberg 2015. Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42(13):1955–1963.31 With permission of Springer.
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival; nr, not reached; CI, confidence interval; PRRT, peptide receptor radionuclide therapy; NA, not applicable.